Global drug-resistance patterns and the management of latent tuberculosis infection in immigrants to the United States

New England Journal of Medicine

Volumn 347, Issue 23, 2002, Pages 1850-1859

  Khan, Kamran ^a,b,e   Muennig, Peter ^d   Behta, Maryam ^a   Zivin, Joshua Graff ^b,c  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b Department of Medicine   (United States)

^c City University of New York ^*  (United States)

^d CITY UNIVERSITY OF NEW YORK MEDICAL SCHOOL   (United States)

^e ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; TUBERCULIN; TUBERCULOSTATIC AGENT;

ARTICLE; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DEVELOPING COUNTRY; ECONOMIC ASPECT; HAITI; HEALTH ECONOMICS; HEALTH SURVEY; HUMAN; IMMIGRANT; MEDICAL DECISION MAKING; MONTE CARLO METHOD; MULTIDRUG RESISTANCE; PHILIPPINES; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; STATISTICAL ANALYSIS; STATISTICAL MODEL; TOXIC HEPATITIS; TUBERCULIN TEST; TUBERCULOSIS; UNITED STATES; VIET NAM;

ANTITUBERCULAR AGENTS; COST SAVINGS; DECISION SUPPORT TECHNIQUES; DRUG RESISTANCE, BACTERIAL; EMIGRATION AND IMMIGRATION; HEALTH CARE COSTS; HUMANS; MASS SCREENING; PREVALENCE; TUBERCULOSIS; UNITED STATES;

EID: 0037028024     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMsa021099     Document Type: Article

References (55)

1. Gushulak BD, MacPherson DW. Population mobility and infectious diseases: The diminishing impact of classical infectious diseases and new approaches for the 21st century. Clin Infect Dis 2000;31:776-80.
2. Talbot EA, Moore M, McCray E, Binkin NJ. Tuberculosis among foreignborn persons in the United States, 1993-1998. JAMA 2000;284:2894-900.
3. Tuberculosis Cases and Case Rates per 100,000 Population by Origin: United States, 1991-2001. Atlanta: Centers for Disease Control and Prevention, 2002. (Accessed November 8, 2002, at http://www.cdc.gov/nchstp/tb/surv/surv2001/pdf/Tabpost4.pdf.)
4. 2000 Decennial Census, Washington, D.C.: Census Bureau, 2002. (Accessed November 8, 2002, at http://www.census.gov/population/www/socdemo/foreign.html.)
5. Geng E, Kreiswirth B, Driver C, et al. Changes in the transmission of tuberculosis in New York City from 1990 to 1999. N Engl J Med 2002;346:1453-8.
6. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Morb Mortal Wkly Rep 2000;49(RR-6):1-51.
7. Geiter L, ed. Ending Neglect: The Elimination of Tuberculosis in the United States. Washington, D.C.: National Academy Press, 2000.
8. Coker R, van Weezenbeek KL. Mandatory screening and treatment of immigrants for latent tuberculosis in the USA: Just restraint? Lancet Infect Dis 2001;1:270-6.
9. Espinal MA, Laszlo A, Simonsen L, et al. Global trends in resistance to antituberculosis drugs. N Engl J Med 2001;344:1294-303.
10. Euro TB. Surveillance of Drug Resistance in Europe. European Commission, 2002. (Accessed November 8, 2002, at http://www.eurotb.org/.)
11. Weis SE, Moonan PK, Pogoda JM, et al. Tuberculosis in the foreign-born population of Tarrant County, Texas, by immigration status. Am J Respir Crit Care Med 2001;164:953-7.
12. Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press, 1996.
13. Comstock GW, Baum C, Snider DE Jr. Isoniazid prophylaxis among Alaskan Eskimos: A final report of the Bethel isoniazid studies. Am Rev Respir Dis 1979;119:827-30.
14. Fairshter RD, Randazzo GP, Garlin J, Wilson AF. Failure of isoniazid prophylaxis after exposure to isoniazid-resistant tuberculosis. Am Rev Respir Dis 1975;112:37-42.
15. Immigration and Naturalization Act, §212, 8 U.S.C. 1182. Washington, D.C.: Immigration and Naturalization Service, 2002. (Accessed November 8, 2002, at http://www.ins.usdoj.gov/graphics/lawsregs/INA.htm.)
16. Drug Topics Red Book: Pharmacy's Fundamental Reference. Montvale, N.J.: Medical Economics, 2000.
17. National Physician Fee Schedule Payment Amount File. Baltimore: Centers for Medicare & Medicaid Services, 2000. (Accessed November 8, 2002, at http://cms.hhs.gov/physicians/pfs/default.asp.)
18. Medicare Payment Systems: Clinical Lab Diagnostic Fee Schedule. Baltimore: Centers for Medicare & Medicaid Services, 2002. (Accessed November 8, 2002, at http://cms.hhs.gov/paymentsystems/default.asp.)
19. Journey to Work and Place of Work. Washington, D.C.: Census Bureau, 2002. (Accessed November 8, 2002, at: http://www.census.gov/population/www/socdemo/journey.html.)
20. Passenger Fares Summary. Washington, D.C.: American Public Transportation Association, 2002. (Accessed November 8, 2002, at: http://www.apta.com/stats/fares/fares.htm.)
21. Motor Gasoline Retail Prices. Washington, D.C.: Department of Energy, 2002. (Accessed November 8, 2002, at http://www.eia.doe.gov/mer/txt/mer9-4.)
22. Motor Vehicle Mileage, Fuel Consumption, and Fuel Rates. Washington, D.C.: Department of Energy, 2002. (Accessed November 8, 2002, at http://www.eia.doe.gov/emeu/mer/txt/mer1-10.)
23. Healthcare Cost and Utilization Project, 1997. Rockville, Md.: Agency for Healthcare Research and Quality, 2002. (Accessed November 8, 2002, at http://www.ahrq.gov/data/hcup/hcupnet.htm.)
24. Medicare Provider and Analysis Review (MEDPAR) of Short-Stay Hospitals. Baltimore: Centers for Medicare & Medicaid Services, 2002. (Accessed November 8, 2002, at http://cms.hhs.gov/statistics/medpar/default.asp.)
25. Brown RE, Miller B, Taylor WR, et al. Health-care expenditures for tuberculosis in the United States. Arch Intern Med 1995;155:1595-600.
26. National Employment and Wage Data from the Occupational Employment Statistics Survey by Occupation, 2000. Washington, D.C.: Bureau of Labor Statistics, Department of Labor, 2002. (Accessed November 8, 2002, at http://www.bls.gov/news.release/ocwage.t01.htm.)
27. Schwartzman K, Menzies D. Tuberculosis screening of immigrants to low-prevalence countries: A cost-effectiveness analysis. Am J Respir Crit Care Med 2000;161:780-9.
28. Diagnostic standards and classification of tuberculosis in adults and children. Am J Respir Crit Care Med 2000;161:1376-95.
29. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: Five years of follow-up in the IUAT trial. Bull World Health Organ 1982;60:555-64.
30. Gordin F, Chaisson RE, Matts JP, et al. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: An international randomized trial. JAMA 2000;283:1445-50.
31. A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Am Rev Respir Dis 1992;145:36-41.
32. Geiter LJ. Results of a randomized, controlled trial to Assess the Toxicity and Patient Adherence with Two Short Course Regimens for the Prevention of Tuberculosis, a Two-Month Regimen of Rifampin and Pyrazinamide or a Four-Month Regimen of Rifampin Only, in Comparison with a Control Regimen of Six-Months-Isoniazid. (Ph.D. [Epi] thesis. Baltimore: School of Hygiene and Public Health, Johns Hopkins University, 1997:180.)
33. King MD, Abdulrahman S, Oladele A, Tapia JR, Stringer E, Blumberg HM. A randomized trial of 2 months of rifampin plus pyrazinamide versus 6 months ofisoniazid for the treatment of latent tuberculosis infection in HIV negative patients. In: Abstracts of the Infectious Diseases Society of America 39th Annual Meeting, San Francisco, October 25-28, 2001:1146. abstract.
34. Cook PP, McNeill EL, Allen M. Comparison of a two month regimen of pyrazinamide and rifampin with a six month regimen of isoniazid for treatment of patients with latent tuberculosis infection. In: Abstracts of the Infectious Diseases Society of America 39th Annual Meeting, San Francisco, October 25-28, 2001:1147. abstract.
35. Jasmer RM, Saukkonen JJ, Blumberg HM, et al. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: A multicenter clinical trial. Ann Intern Med 2002;137:640-7.
36. Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associated with isoniazid preventive therapy: A 7-year survey from a public health tuberculosis clinic. JAMA 1999;281:1014-8.
37. Kochanek KD, Smith BL, Anderson RN. Deaths: Preliminary Data for 1999. National Vital Statistics Reports. Vol. 49. No. 3. Hyattsville, Md.: National Center for Health Statistics, 2001. (DHHS publication no. (PHS) 2001-1120 PRS 01-0358.)
38. Countries & Regions. Washington, D.C.: World Bank Group, 2001. (Accessed November 8, 2002, at http://www.worldbank.org/html/extdr/regions.htm.)
39. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Global burden of tuberculosis: Estimated incidence, prevalence, and mortality by country: WHO Global Surveillance and Monitoring Project. JAMA 1999;282:677-86.
40. Statistics. Washington, D.C.: Immigration and Naturalization Service, 2002. (Accessed November 8, 2002, at http://wvw.ins.gov/graphics/aboutins/statistics/.)
41. Zuber PL, McKenna MT, Binkin NJ, Onorato IM, Castro KG. Long-term risk of tuberculosis among foreign-born persons in the United States. JAMA 1997;278:304-7.
42. Tuberculosis Cases in Foreign-Born Persons by Number of Years in the United States: States, 2000. Atlanta: Centers for Disease Control and Prevention, 2002. (Accessed November 8, 2002, at http://www.cdc.govnchstp/tb/surv/surv2000/pdfs/t20.pdf.)
43. Multiple Cause-of-Death Public-Use File for 1997 Data. Hyattsville, Md.: National Center for Health Statistics, 1997 (software).
44. National Tuberculosis Surveillance System. Atlanta: Centers for Disease Control and Prevention, 1996-2000 (data base).
45. Feeny DH, Furlong W, Boyle M, Torrance GW. Multiattribute Health States Classification Systems: Health Utilities Index, Pharmacoeconomics 1995;7:490-502.
46. A controlled clinical comparison of 6 and 8 months of antituberculosis chemotherapy in the treatment of patients with silicotuberculosis in Hong Kong. Am Rev Respir Dis 1991;143:262-7.
47. Moore M, Onorato IM, McCray E, Castro KG. Trends in drug-resistant tuberculosis in the United States, 1993-1996. JAMA 1997;278:833-7. [Erratum, JAMA 1998;279:656.]
48. Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations - United States, 2001. MMWR Morb Mortal Wkly Rep 2001;50:733-5.
49. Bass JB Jr, Farer LS, Hopewell PC, et al. Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med 1994;149:1359-74.
50. Lollock L. The foreign-Born Population in the United States, March 2000. Current population reports. No. P20-534. Washington, D.C.: Census Bureau, 2001.
51. Consumer Price Indexes. Washington, D.C.: Bureau of Labor Statistics, Department of Labor, 2002. (Accessed November 8, 2002, at http://www.bls.gov/cpi.)
52. Chaisson RE, Armstrong J, Stafford J, Golub J, Bur S. Safety and tolerability of intermittent rifampin/pyrazinamide for the treatment of tuberculosis infection in prisoners. JAMA 2002;288:165-6.
53. McGlynn KA, Lustbader ED, Sharrar RG, Murphy EC, London WT. Isoniazid prophylaxis in hepatitis B carriers. Am Rev Respir Dis 1986;134:666-8.
54. Sadaphal P, Astemborski J, Graham NM, et al. Isoniazid preventive therapy, hepatitis C virus infection, and hepatotoxicity among injection drug users infected with Mycobacterium tuberculosis. Clin Infect Dis 2001;33:1687-91.
55. Granich RM, Moore M, Binkin NJ, Mcray E. Drug-resistant tuberculosis in foreign-born persons from Mexico, the Philippines, and Vietnam - United States, 1993-1997 Int J Tuberc Lung Dis 2001;5:53-8.